EP0959074A3 - Substituted pyrazoles as CRF antagonists - Google Patents

Substituted pyrazoles as CRF antagonists Download PDF

Info

Publication number
EP0959074A3
EP0959074A3 EP99109027A EP99109027A EP0959074A3 EP 0959074 A3 EP0959074 A3 EP 0959074A3 EP 99109027 A EP99109027 A EP 99109027A EP 99109027 A EP99109027 A EP 99109027A EP 0959074 A3 EP0959074 A3 EP 0959074A3
Authority
EP
European Patent Office
Prior art keywords
substituted pyrazoles
crf antagonists
crf
antagonists
pyrazoles
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP99109027A
Other languages
German (de)
English (en)
French (fr)
Other versions
EP0959074A2 (en
Inventor
Gene M. Bright
Willard M. Welch Jr.
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Corp Belgium
Pfizer Corp SRL
Pfizer Inc
Original Assignee
Pfizer Corp Belgium
Pfizer Corp SRL
Pfizer Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Corp Belgium, Pfizer Corp SRL, Pfizer Inc filed Critical Pfizer Corp Belgium
Publication of EP0959074A2 publication Critical patent/EP0959074A2/en
Publication of EP0959074A3 publication Critical patent/EP0959074A3/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/18—One oxygen or sulfur atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Reproductive Health (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Anesthesiology (AREA)
  • Toxicology (AREA)
  • Transplantation (AREA)
  • Communicable Diseases (AREA)
  • AIDS & HIV (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP99109027A 1992-12-17 1993-09-30 Substituted pyrazoles as CRF antagonists Withdrawn EP0959074A3 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US99222892A 1992-12-17 1992-12-17
US992228 1992-12-17
EP93922407A EP0674631B1 (en) 1992-12-17 1993-09-30 Substituted pyrazoles as crf antagonists

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
EP93922407A Division EP0674631B1 (en) 1992-12-17 1993-09-30 Substituted pyrazoles as crf antagonists

Publications (2)

Publication Number Publication Date
EP0959074A2 EP0959074A2 (en) 1999-11-24
EP0959074A3 true EP0959074A3 (en) 2000-06-07

Family

ID=25538068

Family Applications (2)

Application Number Title Priority Date Filing Date
EP99109027A Withdrawn EP0959074A3 (en) 1992-12-17 1993-09-30 Substituted pyrazoles as CRF antagonists
EP93922407A Expired - Lifetime EP0674631B1 (en) 1992-12-17 1993-09-30 Substituted pyrazoles as crf antagonists

Family Applications After (1)

Application Number Title Priority Date Filing Date
EP93922407A Expired - Lifetime EP0674631B1 (en) 1992-12-17 1993-09-30 Substituted pyrazoles as crf antagonists

Country Status (26)

Country Link
EP (2) EP0959074A3 (cs)
JP (1) JP2781661B2 (cs)
KR (1) KR100190730B1 (cs)
CN (1) CN1045293C (cs)
AT (1) ATE187451T1 (cs)
AU (1) AU690079B2 (cs)
BR (1) BR9307664A (cs)
CA (1) CA2150703C (cs)
CZ (1) CZ287925B6 (cs)
DE (1) DE69327254T2 (cs)
DK (1) DK0674631T3 (cs)
EG (1) EG20440A (cs)
ES (1) ES2139676T3 (cs)
FI (1) FI111254B (cs)
GR (1) GR3032461T3 (cs)
HU (1) HUT65822A (cs)
IL (1) IL107947A (cs)
MY (1) MY109522A (cs)
NO (1) NO307884B1 (cs)
NZ (1) NZ256620A (cs)
PL (1) PL175982B1 (cs)
PT (1) PT674631E (cs)
RU (1) RU2130453C1 (cs)
TW (1) TW237455B (cs)
WO (1) WO1994013661A1 (cs)
ZA (1) ZA939406B (cs)

Families Citing this family (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9222253D0 (en) * 1992-10-23 1992-12-09 Celltech Ltd Chemical compounds
GB9304920D0 (en) * 1993-03-10 1993-04-28 Celltech Ltd Chemical compounds
GB9304919D0 (en) * 1993-03-10 1993-04-28 Celltech Ltd Chemical compounds
BR9407799A (pt) 1993-10-12 1997-05-06 Du Pont Merck Pharma Composição de matéria método de tratamento e composição farmaceutica
GB9326600D0 (en) * 1993-12-22 1994-03-02 Celltech Ltd Chemical compounds
WO1995017399A1 (en) * 1993-12-22 1995-06-29 Celltech Therapeutics Limited Trisubstituted phenyl derivatives, processes for their preparation and their use as phosphodiesterase (type iv) inhibitors
KR100263429B1 (ko) * 1994-06-06 2000-08-01 디. 제이. 우드 코르티코트로핀-방출 인자(crf) 길항 활성을 갖는 치환된 피라졸
AU719558B2 (en) * 1994-06-06 2000-05-11 Pfizer Inc. Substituted pyrazoles having corticotropin-releasing factor (CRF) antagonist activity
US5786354A (en) * 1994-06-21 1998-07-28 Celltech Therapeutics, Limited Tri-substituted phenyl derivatives and processes for their preparation
US6245774B1 (en) 1994-06-21 2001-06-12 Celltech Therapeutics Limited Tri-substituted phenyl or pyridine derivatives
GB9412573D0 (en) 1994-06-22 1994-08-10 Celltech Ltd Chemical compounds
GB9412571D0 (en) 1994-06-22 1994-08-10 Celltech Ltd Chemical compounds
US6403599B1 (en) 1995-11-08 2002-06-11 Pfizer Inc Corticotropin releasing factor antagonists
US7125880B1 (en) 1995-06-06 2006-10-24 Pfizer Inc. Corticotropin releasing factor antagonists
GB9523675D0 (en) * 1995-11-20 1996-01-24 Celltech Therapeutics Ltd Chemical compounds
GB9526246D0 (en) * 1995-12-21 1996-02-21 Celltech Therapeutics Ltd Chemical compounds
GB9526245D0 (en) * 1995-12-21 1996-02-21 Celltech Therapeutics Ltd Chemical compounds
GB9608435D0 (en) * 1996-04-24 1996-06-26 Celltech Therapeutics Ltd Chemical compounds
US6011052A (en) * 1996-04-30 2000-01-04 Warner-Lambert Company Pyrazolone derivatives as MCP-1 antagonists
US6124289A (en) * 1996-07-24 2000-09-26 Dupont Pharmaceuticals Co. Azolo triazines and pyrimidines
US6191131B1 (en) 1997-07-23 2001-02-20 Dupont Pharmaceuticals Company Azolo triazines and pyrimidines
US7094782B1 (en) 1996-07-24 2006-08-22 Bristol-Myers Squibb Company Azolo triazines and pyrimidines
US6060478A (en) * 1996-07-24 2000-05-09 Dupont Pharmaceuticals Azolo triazines and pyrimidines
US6313124B1 (en) 1997-07-23 2001-11-06 Dupont Pharmaceuticals Company Tetrazine bicyclic compounds
US5861398A (en) * 1996-08-26 1999-01-19 Alanex Corporation Benzoperimidine-carboxylic acids and derivatives thereof
GB9619284D0 (en) * 1996-09-16 1996-10-30 Celltech Therapeutics Ltd Chemical compounds
WO1998011075A1 (en) * 1996-09-16 1998-03-19 Du Pont Pharmaceuticals Company Pyrazinones and triazinones and their derivatives thereof
GB9622363D0 (en) 1996-10-28 1997-01-08 Celltech Therapeutics Ltd Chemical compounds
US5760225A (en) * 1996-11-15 1998-06-02 Neurogen Corporation Certain pyrazole derivatives as corticotropin-releasing factor receptor CRF1 specific ligands
GB9625184D0 (en) * 1996-12-04 1997-01-22 Celltech Therapeutics Ltd Chemical compounds
US6057329A (en) * 1996-12-23 2000-05-02 Celltech Therapeutics Limited Fused polycyclic 2-aminopyrimidine derivatives
US5723608A (en) 1996-12-31 1998-03-03 Neurogen Corporation 3-aryl substituted pyrazolo 4,3-d!pyrimidine derivatives; corticotropin-releasing factor receptor (CRF1) specific ligands
GB9705361D0 (en) * 1997-03-14 1997-04-30 Celltech Therapeutics Ltd Chemical compounds
ATE247102T1 (de) * 1997-03-26 2003-08-15 Taisho Pharmaceutical Co Ltd 4-tetrahydropyridylpyrimidin-derivate
GB9713087D0 (en) * 1997-06-20 1997-08-27 Celltech Therapeutics Ltd Chemical compounds
US5955471A (en) * 1998-01-13 1999-09-21 Sk Corporation Tetrahydroisoquinolinealkanol derivatives and pharmaceutical compositions containing same
CA2326319A1 (en) 1998-04-02 1999-10-14 Neurogen Corporation Aminoalkyl substituted 5,6,7,8-tetrahydro-9h pyrimidino[2,3-b]indole and 5,6,7,8-tetrahydro-9h-pyrimidino[4,5-b]indole derivatives: crf1 specific ligands
US6472402B1 (en) 1998-04-02 2002-10-29 Neurogen Corporation Aminoalkyl substituted 5,6,7,8-Tetrahydro-9H-Pyridino [2,3-B]indole derivatives
US6531475B1 (en) 1998-11-12 2003-03-11 Neurocrine Biosciences, Inc. CRF receptor antagonists and methods relating thereto
AU755552B2 (en) 1998-11-12 2002-12-12 Neurocrine Biosciences, Inc. CRF receptor antagonists and methods relating thereto
DK1129096T3 (da) 1998-11-12 2003-09-15 Neurocrine Biosciences Inc CRF-receptorantagonister og fremgangsmåder, der er relateret dertil
GB9914258D0 (en) 1999-06-18 1999-08-18 Celltech Therapeutics Ltd Chemical compounds
US6506784B1 (en) 1999-07-01 2003-01-14 3-Dimensional Pharmaceuticals, Inc. Use of 1,3-substituted pyrazol-5-yl sulfonates as pesticides
US6409988B1 (en) 1999-07-01 2002-06-25 3-Dimensional Pharmaceuticals, Inc. Radiolabeled 1-aryl pyrazoles, the synthesis thereof and the use thereof as pest GABA receptor ligands
AU6116800A (en) 1999-07-22 2001-02-13 3-Dimensional Pharmaceuticals, Inc. 1-aryl-3-thioalkyl pyrazoles, the synthesis thereof and the use thereof as insecticides
AU7865000A (en) 1999-10-06 2001-05-10 3-Dimensional Pharmaceuticals, Inc. Fused 1-(2,6-dichloro-4-trifluoromethylphenyl)-pyrazoles, the synthesis thereof and the use thereof as pesticides
GB9924862D0 (en) 1999-10-20 1999-12-22 Celltech Therapeutics Ltd Chemical compounds
TWI271406B (en) 1999-12-13 2007-01-21 Eisai Co Ltd Tricyclic condensed heterocyclic compounds, preparation method of the same and pharmaceuticals comprising the same
US6569885B1 (en) * 1999-12-23 2003-05-27 Icos Corporation Cyclic AMP-specific phosphodiesterase inhibitors
EP1293213A1 (en) * 2000-02-14 2003-03-19 Japan Tobacco Inc. Preventives/remedies for postoperative stress
WO2001062718A1 (fr) * 2000-02-25 2001-08-30 Japan Tobacco, Inc. Dérivé de benzamide et utilisation de celui-ci
GB0016453D0 (en) * 2000-07-04 2000-08-23 Hoffmann La Roche Pyrrole derivatives
GB0016787D0 (en) 2000-07-07 2000-08-30 Pfizer Ltd Compounds useful in therapy
GB0024795D0 (en) * 2000-10-10 2000-11-22 Hoffmann La Roche Pyrazole derivatives for the treatment of viral diseases
US20060287335A1 (en) 2000-11-28 2006-12-21 Wyeth Serotonergic agents for treating sexual dysfunction
US20060223824A1 (en) 2000-11-28 2006-10-05 Wyeth Serotonergic agents
TWI312347B (en) 2001-02-08 2009-07-21 Eisai R&D Man Co Ltd Bicyclic nitrogen-containing condensed ring compounds
PL214231B1 (pl) 2001-04-27 2013-07-31 Eisai R & D Man Co Pochodne pirazolo [1,5-a] pirydyny, kompozycje je zawierajace oraz zastosowanie
CA2449118A1 (en) 2001-05-29 2002-12-05 Schering Aktiengesellschaft Cdk inhibiting pyrimidines, production thereof and their use as medicaments
IL144900A (en) 2001-08-14 2013-12-31 Neurim Pharma 1991 Melatonin and drugs containing it for use in the treatment of primary insomnia, and the manufacture of those drugs
US6638981B2 (en) 2001-08-17 2003-10-28 Epicept Corporation Topical compositions and methods for treating pain
EP1441724B8 (en) * 2001-09-27 2007-10-17 Laboratoires Serono SA Methods of increasing endogenous testosterone levels
US7176216B2 (en) 2002-10-22 2007-02-13 Eisai Co., Ltd. 7-phenylpyrazolopyridine compounds
DK1555265T3 (da) 2002-10-22 2009-06-22 Eisai R&D Man Co Ltd 7-phenylpyrazolopyridin-forbindelser
ES2350977T3 (es) 2002-11-05 2011-01-28 Glaxo Group Limited Agentes antibacterianos.
EP2172197A1 (en) 2002-12-13 2010-04-07 Warner-Lambert Company LLC Octanoic acid derivative to treat fibromyalgia and other pains
US7160888B2 (en) 2003-08-22 2007-01-09 Warner Lambert Company Llc [1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia
TW200800959A (en) 2005-06-10 2008-01-01 Wyeth Corp Piperazine-piperidine antagonists and agonists of the 5-HT1a receptor
CN101384558A (zh) * 2005-12-23 2009-03-11 阿斯利康(瑞典)有限公司 Gaba-b受体调节剂
WO2008011611A2 (en) * 2006-07-21 2008-01-24 Irm Llc Compounds and compositions as itpkb inhibitors
CL2008000119A1 (es) 2007-01-16 2008-05-16 Wyeth Corp Compuestos derivados de pirazol, antagonistas del receptor nicotinico de acetilcolina; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como demencia senil, alzheimer y esquizofrenia.
ATE481400T1 (de) 2007-06-15 2010-10-15 Irm Llc Verbindungen und zusammensetzungen als itpkb- inhibitoren
WO2009104080A2 (en) 2008-02-20 2009-08-27 Targia Pharmaceuticals Cns pharmaceutical compositions and methods of use
MX2010011089A (es) 2008-04-15 2010-11-05 Eisai R&D Man Co Ltd Compuesto de 3-fenilpirazolo[5,1,-b]tiazol.
US8461389B2 (en) 2008-04-18 2013-06-11 University College Dublin, National University Of Ireland, Dublin Psycho-pharmaceuticals
AR078521A1 (es) 2009-10-08 2011-11-16 Eisai R&D Man Co Ltd Compuesto pirazolotiazol
DE102013002393A1 (de) 2013-02-13 2014-08-14 Rauch Landmaschinenfabrik Gmbh Verfahren zur Regelung des Massenstromes an Streugut bei einem Scheibenstreuer
CN114716389A (zh) * 2021-12-31 2022-07-08 北京岳达生物科技有限公司 一种3,5-二乙基异恶唑-4-羧酸的合成方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5063245A (en) * 1990-03-28 1991-11-05 Nova Pharmaceutical Corporation Corticotropin-releasing factor antagonism compounds

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU1427781A1 (ru) * 1987-02-13 1992-04-23 Научно-исследовательский институт фармакологии АМН СССР 4-Аминокарбонил- или 4-аминоэтил-5-метилпиразолы, обладающие способностью регулировать скорость выведени этанола

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5063245A (en) * 1990-03-28 1991-11-05 Nova Pharmaceutical Corporation Corticotropin-releasing factor antagonism compounds

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ANDERSON ET AL.: "Synthesis and evaluation of furan, thiophene and azole bis[(carbamoyloxy)methylderivatives as potential antineoplastic agents", JOURNAL OF MEDICINAL CHEMISTRY., vol. 27, no. 12, 1984, WASHINGTON US, pages 1559 - 1565, XP002108221 *

Also Published As

Publication number Publication date
NO307884B1 (no) 2000-06-13
IL107947A0 (en) 1994-04-12
CZ158295A3 (en) 1995-12-13
CA2150703C (en) 2002-01-08
IL107947A (en) 1998-08-16
KR950704299A (ko) 1995-11-17
AU690079B2 (en) 1998-04-23
DE69327254D1 (de) 2000-01-13
ATE187451T1 (de) 1999-12-15
PT674631E (pt) 2000-04-28
EG20440A (en) 1999-04-29
TW237455B (cs) 1995-01-01
ES2139676T3 (es) 2000-02-16
FI935672L (fi) 1994-06-18
FI111254B (fi) 2003-06-30
KR100190730B1 (ko) 1999-06-01
PL175982B1 (pl) 1999-03-31
EP0674631A1 (en) 1995-10-04
ZA939406B (en) 1995-06-15
DE69327254T2 (de) 2000-03-30
NO952397D0 (no) 1995-06-16
EP0959074A2 (en) 1999-11-24
CA2150703A1 (en) 1994-06-23
JP2781661B2 (ja) 1998-07-30
HUT65822A (en) 1994-07-28
RU2130453C1 (ru) 1999-05-20
CN1045293C (zh) 1999-09-29
GR3032461T3 (en) 2000-05-31
FI935672A0 (fi) 1993-12-16
NO952397L (no) 1995-08-14
CZ287925B6 (cs) 2001-03-14
BR9307664A (pt) 1999-06-29
EP0674631B1 (en) 1999-12-08
JPH08500121A (ja) 1996-01-09
NZ256620A (en) 1996-05-28
MY109522A (en) 1997-02-28
WO1994013661A1 (en) 1994-06-23
DK0674631T3 (da) 2000-04-10
PL309355A1 (en) 1995-10-02
CN1093363A (zh) 1994-10-12
AU5141393A (en) 1994-07-04

Similar Documents

Publication Publication Date Title
EP0959074A3 (en) Substituted pyrazoles as CRF antagonists
CA2192208A1 (en) Substituted pyrazoles
CA2150709A1 (en) Pyrazolopyrimidines
CA2150016A1 (en) Pyrrolopyrimidines as CRF Antagonists
EP0648749A3 (de) N-Cyanoaryl-Stickstoffheterocyclen
CA2263913A1 (en) Substituted 6,6-hetero-bicyclic derivatives
DE69213769D1 (de) Substituierte Pyrazolylpyrazole, Verfahren zu ihre Herstellung, Zwischenprodukte und ihre Verwendung als Herbizide
WO1997043275A3 (de) Neue substituierte pyridylketoenole
DK0674625T3 (da) Aminosubstituerede pyrazoler, der har CRF-antagonistaktivitet
IL114061A0 (en) Methods of administering crf antagonists
EP1114823A3 (en) Substituted benzylamino nitrogen containing non-aromatic heterocycles
CA2134964A1 (en) Bridged Aza-Bicyclic Derivatives as Substance P Antagonists
EP0272533A3 (de) Substituierte Phenoxypyridine
EP0398084A3 (en) Nitro-substituted heterocyclic compounds
WO2001090102A3 (de) 6-heterocyclyl-3-oxo-3,4-dihydro-chinoxaline
ATE184003T1 (de) 4-iminochinoline, verfahren zu ihrer herstellung und ihre verwendung
EP0739901A3 (en) Novel oligoribonucleotide derivatives and application thereof to antiviral agents
EP0433749A3 (de) Pyrazolin-5-on-Derivate
WO1995004719A1 (de) Substituierte 4-carbamoyl-pyrrolin-2-on- und -dihydrofuran-2-on-derivate und deren verwendung als schädlingsbekämpfungsmittel
EP0314428A3 (en) Fungicidal n-pyridyl - haloamides
WO2001010862A3 (de) Substituierte heterocyclylbenzofurane
MY115291A (en) New substituted pyrazole derivatives, processes for their preparation nad their use as herbicides
EP0362634A3 (de) Basische Dihydropyridine, Verfahren zu ihrer Herstellung und ihre Verwendung als Zwischenprodukte
EP0549927A3 (de) Heterocyclisch substituierte Carbamate und Verfahren zu ihrer Herstellung

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19990507

AC Divisional application: reference to earlier application

Ref document number: 674631

Country of ref document: EP

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU NL PT SE

PUAL Search report despatched

Free format text: ORIGINAL CODE: 0009013

AK Designated contracting states

Kind code of ref document: A3

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU NL PT SE

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20060331